<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886299</url>
  </required_header>
  <id_info>
    <org_study_id>CL (746)</org_study_id>
    <nct_id>NCT02886299</nct_id>
  </id_info>
  <brief_title>Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis</brief_title>
  <official_title>Comparative Study of Effects and Safety of Intermittent Low Dose Therapy of Fenofibrate and Simvastatin on Chronic Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <brief_summary>
    <textblock>
      Sixty chronic hemodialysis patients were randomly assigned to receive fenofibrate 100 mg&#xD;
      (group 1, n = 30) or simvastatin 20 mg (group 2, n = 30) three times/week after their&#xD;
      dialysis session. The safety and efficacy of drugs on lipid profile, oxidized low density&#xD;
      lipoproteins (ox-LDL), glutathione peroxidase (GSH-Px) and C-reactive protein (CRP) were&#xD;
      compared before and after 16-week treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized open label parallel study.&#xD;
&#xD;
      The selected patients will be randomly allocated to one of two groups&#xD;
&#xD;
        -  Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days&#xD;
           after the dialysis session (three times per week).&#xD;
&#xD;
        -  Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days&#xD;
           after the dialysis session (3 times per week).&#xD;
&#xD;
      A careful history of all patients including demographic characteristics, physical&#xD;
      examination, chief complaint, past medical history, drug history, familial history, social&#xD;
      history, disease(s).&#xD;
&#xD;
      Monitoring Parameters:&#xD;
&#xD;
      For efficacy, the following parameters are measured:&#xD;
&#xD;
        1. Lipid profile (total cholesterol, HDL, TG and LDL from Friedwald formula [10] {LDL-C=&#xD;
           TC-[HDL + TG\5]). (measured at baseline and every month for 4 months)&#xD;
&#xD;
        2. C-reactive protein (CRP). (measured at baseline and after 4 months)&#xD;
&#xD;
        3. Oxidative stress markers: oxidized LDL and human glutathione peroxidase (measured at&#xD;
           baseline and after 4 months).&#xD;
&#xD;
      For safety: (measured at baseline and every month for 4 months)&#xD;
&#xD;
        1. Observe for signs &amp; symptoms of muscle toxicity and measure phosphocreatine kinase&#xD;
           (CPK).&#xD;
&#xD;
        2. Liver function tests: ALT, AST, ALP &amp; albumin.&#xD;
&#xD;
        3. Urea &amp; serum creatinine. (to monitor renal function)&#xD;
&#xD;
        4. Hemoglobin&#xD;
&#xD;
        5. Other measurements: Body mass index (BMI), Blood Pressure, electrolytes&#xD;
           (Sodium,potassium, calcium, phosphorous) and assess patient compliance by tablet&#xD;
           counting.&#xD;
&#xD;
      Statistical analysis will be used to compare the effects of simvastatin and fenofibrate on&#xD;
      lipid profile, inflammatory marker (CRP) and oxidative stress markers (oxidized LDL and&#xD;
      glutathione peroxidase). In addition, comparing their safety on renal and hepatic functions,&#xD;
      phosphocreatine kinase, blood pressure and blood glucose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxidative stress markers (serum ox-LDL and GSH-Px)</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Fenofibrate/Simvastatin Comparison</condition>
  <arm_group>
    <arm_group_label>Fenofibrate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days after the dialysis session (3 times per week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <arm_group_label>Fenofibrate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <arm_group_label>Simvastatin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Chronic hemodialysis patients with 3 dialysis sessions per week.&#xD;
&#xD;
          3. Lipid profile:&#xD;
&#xD;
               1. Total Cholesterol ≥ 200 mg/dl or LDL ≥ 130 mg/dl.&#xD;
&#xD;
               2. Triglycerides ≥ 150 mg/dl.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous intolerance to fibrates or statins.&#xD;
&#xD;
          2. Use of any fibrates or statins within 6 months prior to study.&#xD;
&#xD;
          3. Hypothyroidism.&#xD;
&#xD;
          4. Active liver disease [unexplained persistent increase in liver enzymes (ALT &amp; AST &gt; 2x&#xD;
             ULN)].&#xD;
&#xD;
          5. Uncontrolled hypertension.&#xD;
&#xD;
          6. History of MI or coronary bypass surgery in last 3 months.&#xD;
&#xD;
          7. Muscle toxicity (Phosphocreatine kinase (CPK) &gt; 2x ULN).&#xD;
&#xD;
          8. Gall bladder disease.&#xD;
&#xD;
          9. Use of any immunosuppressant or steroid.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>September 1, 2016</last_update_submitted>
  <last_update_submitted_qc>September 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Aya Mohammed Abdel Magid Abdel Hamid</investigator_full_name>
    <investigator_title>Teaching Assistant</investigator_title>
  </responsible_party>
  <keyword>Fibrates</keyword>
  <keyword>Statins</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Improved Oxidative Stress</keyword>
  <keyword>Egypt</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

